Doximity shares pare more-than-100% surge after earnings and AI-search update

Doximity shares surged as much as 100% on August 7 after the digital medical platform reported fiscal first-quarter revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million, a 47.7% margin, while highlighting early commercial traction for its AI Search product. The stock closed at $27.40, up 32.5%, after hitting an intraday high of $67.72. Management described AI Search as a potential multibillion-dollar opportunity and said it had closed initial deals with top-20 pharmaceutical manufacturers.

Doximity shares pare more-than-100% surge after earnings and AI-search update - Doximity reported fiscal first-quarter revenue of $156.6 million, up about 7% year over year, and adjusted EBITDA of $74.8 million, or a 47.7% margin. 1 https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results/default.aspx - Shares rose as high as $67.72 during August 7 trading before closing at $27.40, up 32.5% from the prior close. 2 https://www.cnbc.com/2026/08/07/doximity-shares-double-heres-whats-driving-it-.html - Management has described AI Search as a potential multibillion-dollar opportunity and said it had closed initial deals with top-20 pharmaceutical manufacturers. 3 https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx - Prior analyst targets, including JPMorgan’s $26 target and a consensus target near $24.61, were set before the latest report and sat below the August 7 close. 4 https://stockanalysis.com/stocks/docs/forecast/ Doximity shares briefly more than doubled on Friday, August 7, after the digital medical platform reported fiscal first-quarter results and highlighted early commercial traction for its AI Search product. The stock reached $67.72 during the session before giving back much of the gain and closing at $27.40, up 32.5% from the previous close. 1 https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results/default.aspx 2 reddit.com https://www.reddit.com/r/TradeVerseNetwork/comments/1vhjxgr/doximity beats estimates shares explode 76 after/?utm source=openai The central market reaction is verifiable through contemporaneous market coverage and multiple earnings summaries, but the latest company release was not available in the company’s indexed investor-relations archive during this review. The quarter’s headline figures and new guidance should therefore be confirmed directly in the August 6, 2026 Form 8-K or earnings release before publication. investors.doximity.com https://investors.doximity.com/news/default.aspx?utm source=openai A stronger quarter than investors expected Doximity reported fiscal first-quarter revenue of $156.6 million, up roughly 7% from the year-earlier period, and adjusted EBITDA of $74.8 million, representing a 47.7% margin. Those figures were described in contemporaneous earnings summaries as above expectations and were the immediate catalyst for the stock’s move. 1 reddit.com https://www.reddit.com/r/TradeVerseNetwork/comments/1vhjxgr/doximity beats estimates shares explode 76 after/?utm source=openai The company’s previous outlook, issued with its fiscal 2026 results in May, called for fiscal 2027 revenue of $664 million to $676 million and adjusted EBITDA of $323 million to $335 million. Management said fiscal 2027 would require additional investment in AI compute, research and development and marketing, which would weigh on near-term margins. 3 investors.doximity.com https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx?utm source=openai Secondary summaries of the August report put second-quarter revenue guidance at approximately $170 million to $171 million and full-year revenue guidance at approximately $671 million to $681 million. Those figures are material to the stock reaction but remain unresolved here until confirmed against the company’s latest filing. 1 https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results/default.aspx AI Search is the commercial bet Doximity’s AI strategy includes Doximity Ask, its clinical AI assistant, and AI Search, a product aimed at pharmaceutical companies seeking to reach physicians in a clinical-search context. In its prior earnings materials, the company said it had closed initial AI Search deals with top-20 pharmaceutical manufacturers. 3 investors.doximity.com https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx?utm source=openai Management has characterized AI Search as a potential multibillion-dollar addition to Doximity’s addressable market. It has also cautioned that near-term revenue would be limited because the product is new and operates in a regulated market. That makes the latest rally a bet on future monetization rather than proof that AI Search is already a material revenue stream. 3 investors.doximity.com https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx?utm source=openai Doximity has separately reported strong use of its clinical AI tools. A company-sponsored 2026 study included 4,688 side-by-side evaluations by physician residents comparing Doximity Ask with products including OpenEvidence, UpToDate and ChatGPT. The study is company-sponsored and measures participant preferences, not independent clinical validation or revenue performance. 5 https://press.doximity.com/reports/residency-preferences-report-2026.pdf The rally moved beyond earlier targets Doximity entered the report with cautious published expectations. JPMorgan had lowered its price target to $26 from $28 while maintaining a Neutral rating in June, and a consensus tracker recently cited an average target of $24.61 from 21 analysts. 4 https://stockanalysis.com/stocks/docs/forecast/ Those targets predated the August earnings report and may change as analysts update their models. Still, the August 7 close above both levels shows how sharply investors repriced the stock after the reported quarter and AI update. The retreat from the session high also underscored the volatility of the reaction: the stock did not retain the more-than-doubling move. 2 https://www.cnbc.com/2026/08/07/doximity-shares-double-heres-whats-driving-it-.html Doximity ended fiscal 2026 with $749 million in cash, cash equivalents and marketable securities and repurchased $432 million of stock during the year. Its May earnings materials said $493 million remained under its repurchase authorization at March 31. 3 https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx Companies mentioned Further sources 1 Contemporaneous summaries of Doximity’s fiscal 2027 first-quarter results, incl… ↗ https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fiscal-2027-First-Quarter-Financial-Results/default.aspx 2 August 7, 2026 market data and contemporaneous reports on the intraday surge an… ↗ https://www.cnbc.com/2026/08/07/doximity-shares-double-heres-whats-driving-it-.html 3 Doximity fiscal 2026 annual results and prepared earnings remarks covering prio… ↗ https://investors.doximity.com/news/news-details/2026/Doximity-Announces-Fourth-Quarter-and-Fiscal-Year-2026-Financial-Results/default.aspx 4 Analyst price-target data, including JPMorgan’s $26 target and the pre-report c… ↗ https://stockanalysis.com/stocks/docs/forecast/ 5 Doximity-sponsored 2026 resident evaluation of clinical AI tools involving 4,68… ↗ https://press.doximity.com/reports/residency-preferences-report-2026.pdf The stories that matter, in one email. Free — unsubscribe anytime.